Compare · NVO vs ZYME
NVO vs ZYME
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zymeworks Inc. (ZYME): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZYME operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 566.4x ZYME ($393.4M).
- Over the past year, NVO is down 22.5% and ZYME is up 69.0% - ZYME leads by 91.6 points.
- ZYME has been more active in the news (5 items in the past 4 weeks vs 4 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Novo Nordisk A/S
- Zymeworks Inc.
- Price
- $50.31-2.25%
- $24.19-0.10%
- Market cap
- $222.81B
- $393.4M
- 1M return
- +15.47%
- +7.42%
- 1Y return
- -22.53%
- +69.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 4
- 5
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ZYME
- Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
- EVP & Chief Operating Officer Hollywood Mark was granted 939 shares, increasing direct ownership by 0.71% to 133,852 units (SEC Form 4)
- A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
- Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Zymeworks to Acquire Theravance Biopharma, Inc.
- Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
- Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
- Truist resumed coverage on Zymeworks with a new price target
- SEC Form 4 filed by EVP, General Counsel Schneider Paul R
- New insider Schneider Paul R claimed no ownership of stock in the company (SEC Form 3)